Lantheus Holdings, Inc. $LNTH Shares Bought by Intech Investment Management LLC

Intech Investment Management LLC grew its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 28.2% in the 4th quarter, HoldingsChannel.com reports. The fund owned 81,221 shares of the medical equipment provider’s stock after acquiring an additional 17,849 shares during the period. Intech Investment Management LLC’s holdings in Lantheus were worth $5,405,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in LNTH. Hantz Financial Services Inc. increased its stake in Lantheus by 412.5% during the third quarter. Hantz Financial Services Inc. now owns 492 shares of the medical equipment provider’s stock worth $25,000 after acquiring an additional 396 shares during the last quarter. Osterweis Capital Management Inc. purchased a new stake in shares of Lantheus in the second quarter worth about $36,000. Farther Finance Advisors LLC boosted its position in shares of Lantheus by 71.4% in the fourth quarter. Farther Finance Advisors LLC now owns 660 shares of the medical equipment provider’s stock worth $44,000 after buying an additional 275 shares during the period. Larson Financial Group LLC boosted its position in shares of Lantheus by 324.5% in the fourth quarter. Larson Financial Group LLC now owns 658 shares of the medical equipment provider’s stock worth $44,000 after buying an additional 503 shares during the period. Finally, Caitong International Asset Management Co. Ltd purchased a new stake in shares of Lantheus in the third quarter worth about $55,000. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Wall Street Zen downgraded Lantheus from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. JonesTrading downgraded Lantheus from a “buy” rating to a “hold” rating in a research report on Friday, February 27th. Mizuho upped their target price on Lantheus from $100.00 to $115.00 and gave the stock an “outperform” rating in a research report on Wednesday. Truist Financial reaffirmed a “buy” rating and issued a $115.00 target price (up from $98.00) on shares of Lantheus in a research report on Monday, May 11th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $110.00 target price on shares of Lantheus in a research report on Tuesday, March 17th. Eight analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $101.86.

Lantheus Stock Performance

Shares of LNTH opened at $99.30 on Monday. The company has a market capitalization of $6.47 billion, a P/E ratio of 23.93 and a beta of -0.03. Lantheus Holdings, Inc. has a one year low of $47.25 and a one year high of $103.89. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.64 and a current ratio of 2.83. The stock has a 50-day moving average price of $85.66 and a 200 day moving average price of $73.49.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 EPS for the quarter, beating analysts’ consensus estimates of $1.25 by $0.21. The firm had revenue of $377.33 million during the quarter, compared to the consensus estimate of $354.48 million. Lantheus had a return on equity of 29.32% and a net margin of 18.05%.Lantheus’s revenue for the quarter was up 1.2% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.53 earnings per share. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Sell-side analysts forecast that Lantheus Holdings, Inc. will post 4.41 EPS for the current fiscal year.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.